VisionTech, one of the Midwest’s most active angel investing groups, recently featured Novilytic on their blog. The post was presented in Q&A format with Paul Dreier, CEO, being the spokesperson for our company.
The questions are bulleted below and a link to the entire piece with Paul’s answers can be found here: Meet July Pitch Presenter #2: Paul Dreier of Novilytic, the Canary in Pharma’s Coal Mine – VisionTech Partners
Your chief technology officer who developed Novilytic’s technology, Dr. Fred Regnier, is a legend in chemistry and at Purdue. How did you two connect?
Tell me about Novilytic and the unmet need you’re addressing.
You have a clever brand story. Tell me about it.
Explain how your Proteometer works. Is it a device? A process?
What are your competitive advantages?
Do you have any patent protection?
What’s your total addressable market? Are there any secondary markets you might pursue?
What’s your revenue model?
Where are you with commercialization?
What funding round is this?
What is your planned use of funds?
Give three reasons why VisionTech Angels should invest?
We thank VisionTech for their time and for helping us to spread the word about our critical mission!
Comments